45 results
8-K
EX-99.1
ABBV
Abbvie Inc
31 Jul 20
AbbVie Reports Second-Quarter 2020 Financial Results
8:41am
bleeding due to uterine fibroids in pre-menopausal women. Uterine fibroids are the most common type of benign tumor in women of reproductive age … fibroids in pre-menopausal women.
Allergan Aesthetics, an AbbVie company, announced the FDA approved Juvederm Voluma XC for the augmentation of the chin
SC TO-C
EX-99.1
ABBV
Abbvie Inc
26 Apr 18
Information about tender offer
12:00am
evaluated in nearly 1,700 women with moderate-to-severe endometriosis-associated pain. Based on AbbVie’s review of the data, the company remains … and in combination with low-dose hormone (add-back) therapy in women with uterine fibroids. At month six, elagolix, in combination with add-back therapy, met
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 18
AbbVie Reports First-Quarter 2018 Financial Results
12:00am
evaluated in nearly 1,700 women with moderate-to-severe endometriosis-associated pain. Based on AbbVie’s review of the data, the company remains … and in combination with low-dose hormone (add-back) therapy in women with uterine fibroids. At month six, elagolix, in combination with add-back therapy, met
8-K
EX-99.1
ABBV
Abbvie Inc
27 Jul 18
AbbVie Reports Second-Quarter 2018 Financial Results
7:43am
rescue analgesic use, fatigue scores, and pain burden from pivotal Phase 3 studies of elagolix in women with moderate to severe pain associated … with endometriosis. New data from a Phase 2b study highlighting the impact of elagolix on productivity in women with uterine fibroids was also presented
8-K
EX-99.1
ABBV
Abbvie Inc
2 Nov 18
AbbVie Reports Third-Quarter 2018 Financial Results
7:50am
) therapy in premenopausal women with heavy menstrual bleeding associated with uterine fibroids for an additional six months (up to 12 months total … with add-back therapy, reduced heavy menstrual bleeding for up to 12 months, with 87.9 percent of women with uterine fibroids achieving clinical
PX14A6G
u8igx1e
11 Apr 22
Letter to shareholders
4:35pm
8-K
EX-99.1
zcl4vkaf1 35bb1
31 Jan 14
AbbVie Reports Fourth-Quarter and Full-Year 2013 Financial Results
12:00am
8-K
EX-99.1
ylczpvhgqmue73gqnej
30 Jan 15
AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results
12:00am
8-K
EX-99.1
k5kf90
25 Jan 19
AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results
7:46am
8-K
EX-99.1
mr9bel1fet 90fck1sko
1 Nov 19
AbbVie Reports Third-Quarter 2019 Financial Results
7:50am